• HeartBeam posted a shareholder letter outlining a strategic pivot toward heart attack detection using its 3D ECG technology.
• Plan drops a large commercial build-out for its FDA-cleared arrhythmia product, keeping only limited commercialization to support select customers.
• Resources shift to MI detection clinical validation, algorithm development, FDA pathway; MI opportunity estimated at about $15 billion.
• Company cited 134-patient ALIGN-ACS pilot enrollment completion; results accepted for TCT 2026; 500-patient HEADSTART-ACS passed 75% enrollment.
• 12-lead patch to advance toward FDA clearance, with commercialization targeted through a strategic partner; patch market estimated at about $2 billion.
• https://www.heartbeam.com/

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609210831BIZWIRE_USPR_____20260921_BW267743) on September 21, 2026, and is solely responsible for the information contained therein.